MarketCapExport financials
Aileron Therapeutics (ALRN)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Aileron Therapeutics Balance Sheet 2025-2011 | ALRN
Brief overview of Aileron Therapeutics's balance sheet strength
The comparison uses five available annual reports from the 2021–2025 interval.
Assets finished at $24.2 million versus $48.5 million initially, losing -50.2%. The balance sheet contracted.
Funding shifted toward liabilities: they gained +58.2%, compared with -50.2% for assets.
Internal capital represents 70% of the balance sheet, previously 90.6%. This is a strong capital position.
Cash equals 13.3% of the balance sheet, compared with 7.4% five periods ago. This is the readily available cushion.
The balance sheet carries negative retained earnings of -$401.3 million. The figure may result from accumulated losses or an active capital return policy.
Conclusion
Taken together, Aileron Therapeutics's balance sheet indicators point to elevated risk. Asset growth does not offset weak funding sources.
Annual Balance Sheet Aileron Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | - | - | -3.44 M | -6.66 M | -279 K | -5.29 M | -11.9 M | -20.7 M | -3.77 M | - | - | - | - |
Long Term Debt |
- | - | - | - | 69 K | 219 K | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
- | - | 48 K | 33 K | 93 K | - | 446 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 4.59 M | 5.34 M | - | 130 M | 97.7 M | - | - | - | - |
Total Current Liabilities |
6.18 M | 5.75 M | 4.38 M | 3.38 M | 4.51 M | 3.96 M | 5.84 M | 5.37 M | 4.89 M | - | - | - | - | - | - |
Total Liabilities |
7.24 M | 7.8 M | 7.71 M | 3.38 M | 4.58 M | 4.18 M | 10.4 M | 10.7 M | 4.89 M | 134 M | 100 M | - | - | - | - |
Retained Earnings |
-401 M | -351 M | -289 M | -273 M | -245 M | -219 M | -198 M | -168 M | -137 M | -114 M | -96.2 M | - | - | - | - |
Total Assets |
24.2 M | 62.2 M | 106 M | 22 M | 48.5 M | 16.3 M | 26.5 M | 30.3 M | 52.7 M | 22 M | 5.94 M | - | - | - | - |
Cash and Cash Equivalents |
3.22 M | 12.9 M | 17.3 M | 5.19 M | 3.6 M | 7.05 M | 5.31 M | 10.6 M | 11.9 M | - | - | - | - | - | - |
Book Value |
16.9 M | 54.4 M | 98.3 M | 18.6 M | 43.9 M | 12.2 M | 16 M | 19.6 M | 47.8 M | -112 M | -94.3 M | - | - | - | - |
Total Shareholders Equity |
16.9 M | 54.4 M | 98.3 M | 18.6 M | 43.9 M | 12.2 M | 16 M | 19.6 M | 47.8 M | -112 M | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Aileron Therapeutics
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 69 K | 99 K | 128 K | 124 K | - | 4.2 M | 4.33 M | 4.46 M | 4.59 M | 4.59 M | 4.59 M | 4.59 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
14.7 M | 7.52 M | 9.47 M | 7.75 M | 7.8 M | 8.98 M | 8.38 M | 7.86 M | 7.71 M | 1.62 M | 1.2 M | 2.88 M | 3.38 M | 4.54 M | 5.15 M | 4.15 M | 4.58 M | 4.66 M | 4.4 M | 3.25 M | 4.18 M | 4.18 M | 4.18 M | 4.18 M | 10.4 M | 10.4 M | 10.4 M | 10.4 M | 10.7 M | 10.7 M | 10.7 M | 10.7 M | 4.89 M | 4.89 M | 4.89 M | 4.89 M | 4.08 M | 4.08 M | 4.08 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-407 M | -369 M | -364 M | -357 M | -351 M | -310 M | -305 M | -296 M | -289 M | -281 M | -279 M | -278 M | -273 M | -268 M | -262 M | -254 M | -245 M | -239 M | -232 M | -226 M | -219 M | -219 M | -219 M | -219 M | -198 M | -198 M | -198 M | -198 M | -168 M | -168 M | -168 M | -168 M | -137 M | -137 M | -137 M | -137 M | -114 M | -114 M | -114 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
26.3 M | 53.7 M | 57.5 M | 57.6 M | 62.2 M | 104 M | 109 M | 99.2 M | 106 M | 12.8 M | 14 M | 17.2 M | 22 M | 27.2 M | 33.8 M | 40.3 M | 48.5 M | 54.8 M | 60.5 M | 64.7 M | 16.3 M | 16.3 M | 16.3 M | 16.3 M | 26.5 M | 26.5 M | 26.5 M | 26.5 M | 30.3 M | 30.3 M | 30.3 M | 30.3 M | 52.7 M | 52.7 M | 52.7 M | 52.7 M | 22 M | 22 M | 22 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
4.44 M | 4.05 M | 5.72 M | 7.43 M | 12.9 M | 17.7 M | 21.9 M | 12 M | 17.3 M | 12.1 M | 13.2 M | 7.78 M | 5.19 M | 4.84 M | 7.63 M | 7.45 M | 3.6 M | 7.6 M | 10.7 M | 19.3 M | 7.05 M | 7.05 M | 7.05 M | 7.05 M | 5.31 M | 5.31 M | 5.31 M | 5.31 M | 10.6 M | 10.6 M | 10.6 M | 10.6 M | 11.9 M | 11.9 M | 11.9 M | 11.9 M | 20.7 M | 20.7 M | 20.7 M | - | 3.77 M | - | - | - | 6.21 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
11.6 M | 46.2 M | 48 M | 49.9 M | 54.4 M | 95.2 M | 101 M | 91.3 M | 98.3 M | 11.2 M | 12.8 M | 14.3 M | 18.6 M | 22.7 M | 28.6 M | 36.1 M | 43.9 M | 50.1 M | 56.1 M | 61.4 M | 12.2 M | 12.2 M | 12.2 M | 12.2 M | 16 M | 16 M | 16 M | 16 M | 19.6 M | 19.6 M | 19.6 M | 19.6 M | 47.8 M | 47.8 M | 47.8 M | 47.8 M | 17.9 M | 17.9 M | 17.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
11.6 M | 46.2 M | 48 M | 49.9 M | 54.4 M | 95.2 M | 101 M | 91.3 M | - | 11.2 M | 12.8 M | 14.3 M | 18.6 M | 22.7 M | 28.6 M | 36.1 M | 43.9 M | 50.1 M | 56.1 M | 61.4 M | 12.2 M | 12.2 M | 12.2 M | 12.2 M | 16 M | 16 M | 16 M | 16 M | 19.6 M | 19.6 M | 19.6 M | 19.6 M | 47.8 M | 47.8 M | 47.8 M | 47.8 M | -112 M | -112 M | -112 M | - | -94.3 M | - | - | - | -82 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Aileron Therapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Russia
USA
Canada
Niderland
Israel
Schweiz
Australia
Britain
